Combined Inhibition of IGF-1R/IR and Src Family Kinases Enhances Antitumor Effects in Prostate Cancer by Decreasing Activated Survival Pathways

• Farshid Dayyani,

  Affiliation Department of Genitourinary Medical Oncology and David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Nila U. Parikh,

  Affiliation Department of Genitourinary Medical Oncology and David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Andreas S. Varkaris,

  Affiliation Department of Genitourinary Medical Oncology and David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Jian H. Song,

  Affiliation Department of Genitourinary Medical Oncology and David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Shhyam Moorthy,

  Affiliation Department of Genitourinary Medical Oncology and David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Tanushree Chatterji,

  Affiliations Department of Genitourinary Medical Oncology and David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, Program in Cancer Metastasis, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, United States of America

  ⨯
• Sankar N. Maity,

  Affiliation Department of Genitourinary Medical Oncology and David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Adam R. Wolfe,

  Affiliation Department of Genitourinary Medical Oncology and David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Joan M. Carboni,

  Affiliation Department of Pharmaceutical Candidate Organization, Bristol-Myers Squibb Company, Princeton, New Jersey, United States of America

  ⨯
• Marco M. Gottardis,

  Affiliation Department of Pharmaceutical Candidate Organization, Bristol-Myers Squibb Company, Princeton, New Jersey, United States of America

  ⨯
• Christopher J. Logothetis,

  Affiliation Department of Genitourinary Medical Oncology and David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Gary E. Gallick

  * E-mail: ggallick@mdanderson.org

  Affiliations Department of Genitourinary Medical Oncology and David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, Program in Cancer Metastasis, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, United States of America, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, United States of America

  ⨯